Healthcare & Pharmaceuticals

Pfizer in talks over full license for COVID-19 vaccine in Singapore

1 minute read

A medical worker prepares to dilute a vial of Pfizer-BioNTech vaccine at a coronavirus disease (COVID-19) vaccination center in Singapore March 8, 2021. REUTERS/Edgar Su

SINGAPORE, Sept 24 (Reuters) - Pfizer Inc (PFE.N) is in discussions with Singapore's Health Sciences Authority regarding obtaining a full license application for its COVID-19 vaccine, the company said in response to a query from Reuters.

Pfizer-BioNTech's (22UAy.DE) COVID-19 vaccine has interim authorisation under the pandemic special access route in Singapore. The U.S. Food and Drug Administration granted full approval to the vaccine last month. read more

Kenneth Mak, Singapore's director of medical services, said in a briefing on Friday Pfizer and Moderna (MRNA.O) had not submitted applications for full registration to authorities.

Singapore has not made COVID-19 vaccination compulsory, saying the Pfizer and Moderna shots only have emergency approval, although it has limited activities such as eating out for the unvaccinated.

Some experts say full registration could pave the way to make vaccination mandatory. read more

Reporting by Aradhana Aravindan and Chen Lin in Singapore Editing by Ed Davies

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters